Chelsea Therapeutics International Ltd. Earnings Cheat Sheet: Loss Made Worse but Not as Bad as Analysts’ Thought

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) reported its results for the third quarter. Chelsea Therapeutics International is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative pharmaceutical products.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Chelsea Therapeutics International Earnings Cheat Sheet for the Third Quarter

Results: Loss widened to $10.9 million (18 cents per diluted share) from $8.8 million (loss of 22 cents per share) in the same quarter a year earlier.

Actual vs. Wall St. Expectations: CHTP beat the mean analyst estimate of a loss of 27 cents per share.

Quoting Management: “People with symptomatic neurogenic orthostatic hypotension face extraordinary challenges every day,” commented Dr. Simon Pedder, President and CEO of Chelsea. “The filing of our new drug application during the third quarter was a significant achievement that has been several years in the making and reflects our team’s commitment to these patients. In reaching this goal, we believe we took a significant step toward making a meaningful new treatment option available to patients whose lives have been impacted by the symptoms of NOH. We are highly confident in the effectiveness of Northera, the strength of our filing and the abilities of our sales and marketing team and look forward toward an anticipated U.S. approval and launch of Northera next year.”

Key Stats:

The company has now beaten estimates the last two quarters. In the second quarter, it topped expectations with a loss of -22 cents versus a mean estimate of a loss of 25 cents per share.

Looking Forward: The average estimate for the fourth quarter is steady at 30 cents a share. The average estimate hasn’t changed from $1.04 per share for the fiscal year.

Competitors to Watch: Mylan Inc. (NASDAQ:MYL), Impax Laboratories, Inc. (NASDAQ:IPXL), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Johnson & Johnson (NYSE:JNJ), Bristol Myers Squibb Co. (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Pfizer Inc. (NYSE:PFE), Novartis AG (NYSE:NVS), Amgen, Inc. (NASDAQ:AMGN), and Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

(Source: Xignite Financials)